Cogent Biosciences (COGT) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cogent Biosciences (COGT) has outperformed Vaxcyte (PCVX) over the past year, gaining 93.1% versus a gain of 59.6%. Over five years, COGT leads with a +225.5% price change compared with +166.3% for PCVX. Vaxcyte is the larger company by market cap ($9.67 billion vs $5.22 billion), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | PCVX |
|---|---|---|
| Share price | $30.08 | $65.02 |
| Market cap | $5.22B | $9.67B |
| 1-day change | -0.20% | -2.90% |
| YTD return | -15.32% | +40.91% |
| 1-year return | +93.07% | +59.59% |
| 5-year return | +225.54% | +166.35% |
| EPS (TTM) | $-2.16 | $-7.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-328.94M | $-766.63M |
| 52-week high | $43.73 | $90.75 |
| 52-week low | $13.78 | $39.87 |
| Distance from 52-week high | -31.21% | -28.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +85.57% | +79.96% |
| Average volume | 1.90M | 1.66M |
| Shares outstanding | 173.52M | 148.81M |
| Employees | 258 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COGT has outperformed PCVX by 33.5 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
COGT vs PCVX FAQ
Which is bigger, Cogent Biosciences or Vaxcyte?
Vaxcyte (PCVX) is larger, with a market capitalization of $9.67B compared with $5.22B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, COGT or PCVX?
COGT returned +93.07% over the past 12 months, compared with +59.59% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Vaxcyte in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Cogent Biosciences and Biotechnology: Biological Products (No Diagnostic Substances) for Vaxcyte.